Hematologic Cancer
38
12
14
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.6%
1 terminated out of 38 trials
90.0%
+3.4% vs benchmark
3%
1 trials in Phase 3/4
22%
2 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (38)
Rutgers University Study of the Genetics of Blood Cancers
The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Home-based Intravenous Cytarabine Treatment for Acute Myeloid Leukemia: a National Danish Study of Feasibility, Costs, and Implementation
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy
Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer
The Florida ASCENT Study
Improving Comprehensive Care of Cancer Patients
The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
Intervention for Fatigue in HCT Recipients
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Avera Cancer Sequencing and Analytics Protocol (ASAP)
The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating
Discontinuation Study
Coverage and Cost of Care Links- Telehealth
Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation
Precision Physical Exercise for Personalized Onco-Hematology.
Hypnosis: a Path to Appeasement
Symptom Management for YA Cancer Survivors